© 2004 by European Society of Cardiology
Copyright © 2004, European Society of Cardiology
Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion
aInstitute of Cardiovascular Sciences, St. Boniface Research Centre, Department of Human Anatomy and Cell Science and Physiology, University of Manitoba, 351 Tache Avenue, Winnipeg, Manitoba, Canada R2H 2A6
bInstitut de Pharmacologie et de Biologie Structurale du CNRS, 205 Route de Narbonne, 31077 Toulouse Cedex 4, France
* Corresponding author. Tel.: +1-204-235-3519; fax: +1-204-233-6723. Email address: ekardami{at}sbrc.ca
Objective: Fibroblast growth factor-2 (FGF-2), given during ischemia or during reperfusion of the ischemic heart is cardioprotective, but its mitogenic activity may limit possible clinical applications. We have tested the cardioprotective potential of a non-mitogenic FGF-2 mutant (S117A) that no longer activates casein kinase 2 (CK2) in both acute and long-term studies. Methods and results: To test effects during reperfusion, the ex vivo rat heart, subjected to 30 min of global ischemia and 60 min of reperfusion was used. S117A FGF-2 administered during reperfusion protected against myocardial contractile dysfunction, activated protein kinase C and decreased the release of cytochrome C in the cytosol. To study effects on ischemic myocytes in the absence of reperfusion, myocardial infarction (MI) was induced in the rat model by irreversible left coronary ligation. S117A-, wild type (wt)-FGF-2 or saline, were administered by intramyocardial injection into the ischemic ventricular wall. One day later, infarct size (assessed by tetrazolium staining), and plasma cardiac troponin T levels (assessed by Western blotting) were significantly decreased in the S117A FGF-2-, compared to the saline-treated group. Systolic pressure, rates of contraction and relaxation and developed pressure, assessed in the Langendorff mode, were significantly improved in the S117-FGF-2 group. Improved ejection fraction and fractional shortening in the S117A-treated group were maintained up to, but not beyond, 7 days post-MI. In comparison, improvements were maintained in the wt-FGF-2-treated group at least up to 6 weeks post-MI. At 6 weeks post-MI, small vessel density (assessed by immunofluorescence-based detection) in the scar bordering viable myocardium was similar between S117A-FGF-2- and saline-treated hearts, but significantly increased in the wt-FGF-2-treated group. This was accompanied by increased coronary flow in the wt-, but not S117A-FGF-2-treated hearts, compared to controls. Conclusion: The ability of FGF-2, administered during ischemia or during reperfusion, to protect the myocardium acutely from tissue loss and dysfunction is independent of its potential for CK2 activation and angiogenesis. Non-angiogenic S117A-FGF-2 may be considered in therapies aiming for acute prevention of reperfusion-associated pathologies, especially in cases where use of mitogens is counter-indicated.
KEYWORDS Cardioprotection; Growth factors; CK2; Infarction; Reperfusion; Protein therapy
1 Current address: Scripps Research Institute, La Jolla, CA, USA.
Time for primary review 24 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Srisakuldee, M. M. Jeyaraman, B. E. Nickel, S. Tanguy, Z.-S. Jiang, and E. Kardami Phosphorylation of connexin-43 at serine 262 promotes a cardiac injury-resistant state Cardiovasc Res, September 1, 2009; 83(4): 672 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Hausenloy and D. M. Yellon Cardioprotective growth factors Cardiovasc Res, July 15, 2009; 83(2): 179 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. G. Langdon, S. C. Goetz, A. E. Berg, J. T. Swanik, and F. L. Conlon SHP-2 is required for the maintenance of cardiac progenitors Development, November 15, 2007; 134(22): 4119 - 4130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A.I. Virag, M. L. Rolle, J. Reece, S. Hardouin, E. O. Feigl, and C. E. Murry Fibroblast Growth Factor-2 Regulates Myocardial Infarct Repair: Effects on Cell Proliferation, Scar Contraction, and Ventricular Function Am. J. Pathol., November 1, 2007; 171(5): 1431 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kaneko, Y. Yonemitsu, T. Fujii, M. Onimaru, C.-H. Jin, M. Inoue, M. Hasegawa, T. Onohara, Y. Maehara, and K. Sueishi A free radical scavenger but not FGF-2-mediated angiogenic therapy rescues myonephropathic metabolic syndrome in severe hindlimb ischemia Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1484 - H1492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Suzuki, T.-C. Lee, J. A. Fallavollita, and J. M. Canty Jr Adenoviral Gene Transfer of FGF-5 to Hibernating Myocardium Improves Function and Stimulates Myocytes to Hypertrophy and Reenter the Cell Cycle Circ. Res., April 15, 2005; 96(7): 767 - 775. [Abstract] [Full Text] [PDF]
|
|